Immunity Linker Compound for Bacterial Infection Therapy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for bacterial infections, especially those caused by gram-negative bacteria, face challenges due to antibiotic resistance mechanisms, making it difficult to develop effective therapies that can overcome resistance and provide broad-spectrum activity.

Innovation Solution

A compound comprising a cationic peptide conjugated with a carbohydrate molecule capable of binding to human anti-alpha-galactosyl antibodies, which recruits natural antibodies to the bacterial surface, promoting complement activation and phagocytosis, thereby overcoming antibiotic resistance.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional antibiotics are used to treat bacterial infections, then bacterial growth is inhibited, but antibiotic resistance mechanisms prevent effective action

Engineering Contradiction:

Improveeffectiveness of treatmentVSAvoidbacterial resistance mechanisms

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent uses an immunity linker molecule as an intermediary that connects the carbohydrate antigen to the bacterial surface. This linker mediates the interaction between pre-existing natural antibodies and bacterial components, enabling immune recruitment without direct antibiotic action. The linker translates bacterial presence into an immune-recruitable signal, bypassing antibiotic resistance mechanisms.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention leverages the patient's own pre-existing natural antibodies and immune system components to fight the infection. Instead of introducing external antimicrobial agents that bacteria can resist, the system activates the body's inherent immune defenses, making the treatment self-service and automatically adaptive to the specific bacterial threat.

Inventive Principle:

Principle #25Self-service

2Reliability

If new antibiotics are developed to target resistant strains, then treatment effectiveness improves, but complex resistance mechanisms make drug development difficult

Engineering Contradiction:

Improvetreatment effectiveness against resistant strainsVSAvoidcomplexity of resistance mechanisms

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

Instead of trying to overcome bacterial resistance mechanisms by developing more sophisticated antibiotics, the invention inverts the approach by using bacterial components themselves (carbohydrate antigens) as the therapeutic agent. The strategy shifts from attacking bacteria with external chemicals to harnessing the bacteria's own molecular structures to trigger an immune response.

Inventive Principle:

Principle #13The other way round (Inversion)

Solution Approach 2:

The immunity linker molecule serves multiple functions: it acts as a conjugation bridge between carbohydrate antigens and delivery vehicles, functions as an immunogen to stimulate antibody production, and serves as a targeting vehicle to deliver immune activators to bacterial surfaces. This multi-functionality simplifies the overall therapeutic approach compared to developing multiple specialized antibiotics for different resistance mechanisms.

Inventive Principle:

Principle #6Universality (Multi-functionality)

3Adaptability or versatility

If immunity linker molecules are used to recruit natural antibodies, then immune response is redirected to target pathogen, but novel molecules are needed to overcome existing resistance

Engineering Contradiction:

Improveimmune response redirectionVSAvoidavailability of novel immunity linker molecules

Core Design Contradiction:

Adaptability or versatilityVSEase of manufacture

Solution Approach 1:

The invention uses simplified models and analogs of natural immunity linker structures to develop therapeutic compounds. By studying and replicating the key functional features of natural linkers in synthetic or semi-synthetic molecules, the patent makes novel immunity linkers more accessible and manufacturable while retaining their immune-recruiting capabilities.

Inventive Principle:

Principle #26Copying

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The compound demonstrates potential as a novel therapy for bacterial infections, including multi-drug resistant strains, by leveraging the immune system's natural response to target bacteria effectively, independent of antibiotic resistance mechanisms.

Implementation Method 1

a carbohydrate molecule capable of binding to a human anti-alpha-galactosyl antibody

Methodology Applied

Scientific EffectAntibody-antigen binding:

Implementation Method 2

promoting complement activation and phagocytosis

Methodology Applied

Scientific EffectComplement activation:

Implementation Method 3

L represents a binding moiety selected from a cationic anti-microbial peptide

Methodology Applied

Scientific EffectElectrostatic interaction:

Data Source

PatentUS11014966B2Compounds and therapeutics uses thereof

Publication Date: 2021.05.25 CENTAURI THERAPEUTICS LTD

AI summary

The invention relates to novel compounds with the ability to link an immune response to a pathogen, to the use of said compounds in a disease or disorder mediated and/or caused by an infective agent, to compositions containing said compounds, processes for their preparation and to novel intermediates used in said process.